Journal of Drugs in Dermatology最新文献_第7页

Use of an Eczema Moisturizer or Cream Provides Immediate, Sustained Itch Relief in Eczema-Prone Individuals. 使用湿疹保湿霜或霜提供即时，持续的瘙痒缓解湿疹易发个体。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-08-01 DOI: 10.36849/JDD.10110

Thu Q Nguyen, Sindhu Garimella, Christine Emesiani, Matthew Meckfessel

{"title":"Use of an Eczema Moisturizer or Cream Provides Immediate, Sustained Itch Relief in Eczema-Prone Individuals.","authors":"Thu Q Nguyen, Sindhu Garimella, Christine Emesiani, Matthew Meckfessel","doi":"10.36849/JDD.10110","DOIUrl":"10.36849/JDD.10110","url":null,"abstract":"Background: Eczema is a prevalent, chronic skin condition that affects up to 10% of adults globally and is characterized by recurrent eczematous lesions. Intense itch is often the most burdensome symptom, leading to sleep disturbances and declining quality of life. Additionally, itch–scratch cycles perpetuate skin barrier damage and inflammation. Regular skincare with moisturizers is recognized as a cornerstone of eczema management.Objectives: This study evaluated the itch relief and safety of Cetaphil® Restoraderm Eczema Soothing Moisturizer (eczema moisturizer) and Cetaphil® Restoraderm Eczema Rapid Relief Cream (eczema cream; Galderma Laboratories, LP, Fort Worth, TX) in individuals with eczema-prone skin.Methods: Thirty-three participants with bilateral eczema-prone skin and mild-to-moderate itch were randomized to blinded, split-body application of the products. Evaluations over 24 hours included time to onset of itch relief, grading of itch severity (11-point itch severity numerical rating scale [NRS]), self-assessment questionnaire (4-point structured scale), and safety assessments.Results: The eczema moisturizer and the eczema cream provided rapid itch relief after a single application, with mean times to itch relief of 38 seconds and 43 seconds, respectively. Both treatments significantly reduced itch severity from baseline by 98% to 99% at 24 hours (eczema moisturizer mean NRS: 0.03; P<0.0001; eczema cream mean NRS: 0.09; P<0.0001). Self-assessment questionnaires demonstrated high participant satisfaction with both products after a single application.Conclusion: Single applications of eczema moisturizer and eczema cream were well tolerated, well perceived by participants, and provided rapid and sustained itch relief over 24 hours. &nbsp.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 8","pages":"737-741"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clascoterone Cream 1% is Safe and Effective for Papulopustular Rosacea: A Phase 2 Clinical Trial. 1% Clascoterone乳膏治疗丘疹性酒渣鼻安全有效：2期临床试验

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-08-01 DOI: 10.36849/JDD.10040

Lucie Joerg, Kayla Zafar, Margaret Kabakova, Jennifer Y Wang, Julia Stolyar, Jenna Zudell, Jared Jagdeo

{"title":"Clascoterone Cream 1% is Safe and Effective for Papulopustular Rosacea: A Phase 2 Clinical Trial.","authors":"Lucie Joerg, Kayla Zafar, Margaret Kabakova, Jennifer Y Wang, Julia Stolyar, Jenna Zudell, Jared Jagdeo","doi":"10.36849/JDD.10040","DOIUrl":"10.36849/JDD.10040","url":null,"abstract":"Background: Papulopustular rosacea (PPR) is a chronic inflammatory facial dermatosis with a need for well-tolerated and effective topical therapies. Clascoterone cream 1% is an androgen receptor inhibitor and a promising novel treatment for PPR.Methods: In this single-center, single-arm, phase 2 pilot study, adults with PPR applied clascoterone cream 1% twice daily to the face. The primary endpoint was biopsy-proven change in mean sebaceous gland number and diameter over 12 weeks. Secondary endpoints included Dermatology Life Quality Index (DLQI), patient-reported outcomes (PROs), and prevalence of adverse events.Results: Twenty participants were enrolled, and 18 completed the study. Mean sebaceous gland count decreased significantly (4.94 ± 1.98 to 3.61 ± 2.33; P=0.012). Mean gland diameter also decreased, although not significantly (P=0.182). Mean DLQI scores significantly improved (7.5 ± 5.8 to 3.3 ± 5.6; P=0.029). PRO scores were favorable for papules/pustules (3.2 ± 1.1), facial redness (2.7 ± 1.0), general skin appearance (2.7 ± 1.1), and overall treatment satisfaction (3.1 ± 0.7). The treatment was well tolerated, with no serious adverse events. Mild, transient dryness (n=1) and eye irritation (n=1) resolved without intervention.Conclusion: Clascoterone cream 1% demonstrated favorable tolerability, safety, and efficacy in PPR, with significant improvements in sebaceous gland count and patient-centered outcomes. These findings support the therapeutic potential of clascoterone cream 1% for the treatment of PPR. &nbsp.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 8","pages":"701-707"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sun Protection: Beyond Sunscreen. 防晒：除了防晒霜。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-08-01 DOI: 10.36849/JDD.9675

Nari Lee, Susruthi Rajanala, Jeffrey S Dover

引用次数: 0

Improved Sleep Quality in Psoriasis Patients Under Biologicals: A Prospective Observational Study. 生物制剂改善银屑病患者睡眠质量：一项前瞻性观察研究

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-08-01 DOI: 10.36849/JDD.9298

David A De Luca, Cristian Papara, Lena Pommerien, Tomasz Hawro, Diamant Thaçi

{"title":"Improved Sleep Quality in Psoriasis Patients Under Biologicals: A Prospective Observational Study.","authors":"David A De Luca, Cristian Papara, Lena Pommerien, Tomasz Hawro, Diamant Thaçi","doi":"10.36849/JDD.9298","DOIUrl":"10.36849/JDD.9298","url":null,"abstract":"Background: Sleep disorders are an underappreciated component of psoriasis-related morbidity. Biologic therapies targeting IL-17 and IL-23 may improve sleep quality by reducing systemic inflammation and improving signs and symptoms.Objective: To explore the association between moderate-to-severe psoriasis and sleep quality, as well to determine if IL-17 and IL-23 inhibitors may improve sleep disorders over 16 weeks.Methods: This prospective open, single center, observational cohort study enrolled patients with moderate-to-severe psoriasis treated with IL-17 or IL-23 inhibitors. Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), pruritus, pain (measured using numeric scales for maximum and average intensity), and sleep quality (Pittsburgh Sleep Quality Index, PSQI) were evaluated at baseline, week 4, and week 16.Results: Seventy patients exhibited moderate sleep impairment at baseline (mean PSQI 7.57). Pruritus and pain correlated significantly with poor sleep quality. Both IL-17 (n=30) and IL-23 inhibitors (n=40) significantly improved PASI, DLQI, pruritus, pain, and PSQI scores by week 16. IL-23 inhibitors demonstrated earlier PSQI improvement at week 4 (P=0.0057), while IL-17 inhibitors showed significant improvement only by week 16 in adjusted models (P=0.03). Regression analyses confirmed improvements in sleep remained significant after adjusting for confounders.Conclusion: Biologic therapy significantly improves sleep quality primarily through symptom control. IL-23 blockade might offer faster onset of sleep benefits, although both IL-17 and IL-23 therapies effectively improved sleep by week 16. Sleep quality may represent a meaningful therapeutic response measure in psoriasis management. &nbsp.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 8","pages":"726-731"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne: Pooled Analysis by Age and Sex. 克林霉素磷酸1.2%/阿达帕烯0.15%/过氧化苯甲酰3.1%凝胶治疗痤疮：按年龄和性别汇总分析。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-08-01 DOI: 10.36849/JDD.9878

Julie C Harper, Heather C Woolery-Lloyd, Linda Stein Gold, Hilary Baldwin, Valerie D Callender, Michael Gold, Adelaide A Hebert, Eric Guenin, Leon H Kircik

{"title":"Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne: Pooled Analysis by Age and Sex.","authors":"Julie C Harper, Heather C Woolery-Lloyd, Linda Stein Gold, Hilary Baldwin, Valerie D Callender, Michael Gold, Adelaide A Hebert, Eric Guenin, Leon H Kircik","doi":"10.36849/JDD.9878","DOIUrl":"10.36849/JDD.9878","url":null,"abstract":"Background: Acne pathophysiology and presentation may differ by patient age or sex. In clinical trials, clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel demonstrated efficacy and a positive safety profile in participants with moderate-to-severe acne. This post hoc analysis evaluated CAB efficacy/safety by age and sex.Methods: In one phase 2 and two phase 3 double-blind, randomized, 12-week trials, participants aged ≥9 years with moderate to severe acne applied once-daily CAB or vehicle. Efficacy endpoints included Evaluator's Global Severity Score ≥2-grade reduction from baseline and clear/almost clear (treatment success) and least squares mean changes from baseline in inflammatory/noninflammatory lesions. Treatment-emergent adverse events (TEAEs) were assessed. Pooled data were analyzed by subgroups: younger (9-24 years; n=274) and older females (≥25 years; n=121); younger (n=241) and older males (n=21).Results: At week 12, in all subgroups, treatment success was greater with CAB (42.3%-54.1%) than with vehicle (15.0%-22.5%), and lesion reductions were ≥70% with CAB versus 44.5%–55.2% with vehicle. For all efficacy endpoints, CAB was superior to vehicle for younger participants and older females (P≤0.05, all). CAB TEAE rates were consistent with the overall population.Conclusions: In 3 clinical trials, CAB, the only fixed-dose, triple-combination topical for acne, demonstrated ≥70% lesion reductions, with good tolerability regardless of participants' sex or age. &nbsp.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 8","pages":"708-716"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atopic Dermatitis Flare Following Initiation of Nemolizumab. 开始使用奈莫单抗后的特应性皮炎发作。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-08-01 DOI: 10.36849/JDD.9249

Olivia M Burke, Jacob Beer, Scott A Elman

引用次数: 0

Reddit for Redness: A Cross-Sectional Analysis of the r/Rosacea Forum. 红发：r/酒渣鼻论坛的横断面分析。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-08-01 DOI: 10.36849/JDD.9436

Joshua Kotlyar, Robert Adler, Ugwumsinachi Nwaubani, William Mark Richardson, Justin W Marson

引用次数: 0

1927 nm Diode Laser for Infraorbital Hyperpigmentation in Skin of Color: Safe and Effective Approach. 纳米二极管激光治疗有色皮肤眶下色素沉着：安全有效的方法。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-07-01 DOI: 10.36849/JDD.9190

Leslie M Garza-García, Payvand Kamrani, Maya Firsowicz, Sabrina G Fabi

{"title":"1927 nm Diode Laser for Infraorbital Hyperpigmentation in Skin of Color: Safe and Effective Approach.","authors":"Leslie M Garza-García, Payvand Kamrani, Maya Firsowicz, Sabrina G Fabi","doi":"10.36849/JDD.9190","DOIUrl":"10.36849/JDD.9190","url":null,"abstract":"Background: Infraorbital hyperpigmentation (IOH) is a common aesthetic concern with multifactorial pathogenesis, especially prevalent in patients with skin of color (SOC). Its management remains challenging due to the delicate anatomy of the periorbital area and the increased risk of post-inflammatory hyperpigmentation associated with many energy-based treatments.Objective: To evaluate the clinical efficacy and safety of a 1927 nm non-ablative fractional diode laser in the treatment of IOH in patients with SOC.Methods: We present a case series of 4 female patients with Fitzpatrick skin types III to IV and clinical diagnoses of IOH. All patients were treated at a single dermatologic practice using the 1927 nm Clear + Brilliant Permea® laser. Each patient received eight non-ablative fractional passes at a high treatment level. Most patients did not receive additional topical therapies. Clinical outcomes are evaluated based on physician observation and patient-reported satisfaction.Results: All patients demonstrated progressive improvement in periorbital pigmentation, increased brightness, and enhanced skin texture. Results were noticeable within weeks of treatment and were maintained over time. No adverse effects, including post-inflammatory hyperpigmentation, were observed.Conclusion: The 1927 nm diode laser appears to be a safe and effective option for the treatment of infraorbital hyperpigmentation in patients with SOC. Its favorable safety profile and gradual clinical improvement make it a promising tool for addressing pigmentary and structural components of IOH. Further controlled studies are needed to validate these findings. &nbsp.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 7","pages":"666-669"},"PeriodicalIF":2.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Brief Review on the Use of Injectable Facial Fillers Among Transgender Women. 变性女性面部注射填充物的应用综述。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-07-01 DOI: 10.36849/JDD.9509

Vincent Pecora, Sheila Sharifi, Alexis Carrington, Angelo Landriscina, Klint Peebles

引用次数: 0

Alopecia Areata in Children and the Emerging Role of JAK Inhibitors. 儿童斑秃和JAK抑制剂的新作用。

IF 2.2 4区医学

Journal of Drugs in Dermatology Pub Date : 2026-07-01 DOI: 10.36849/JDD.9565

Jordan Jafarnia, Riley Shin, Kennedy Cook, Kay Chi Pua, Alisha Kashyap, Rashid M Rashid

引用次数: 0